Published in J Clin Invest on June 01, 1993
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med (2006) 2.47
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood (2003) 2.20
Role of NFkappaB in the mortality of sepsis. J Clin Invest (1997) 2.18
Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A (2001) 2.07
Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol (2004) 1.69
Host innate immune responses to sepsis. Virulence (2013) 1.66
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood (2002) 1.64
Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care (2002) 1.59
Blood coagulation, inflammation, and malaria. Microcirculation (2008) 1.54
Science review: role of coagulation protease cascades in sepsis. Crit Care (2002) 1.37
Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol (2005) 1.37
Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One (2012) 1.36
Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol (2007) 1.34
Roles of protease-activated receptors in a mouse model of endotoxemia. Blood (2006) 1.32
Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci U S A (1994) 1.31
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest (1996) 1.29
Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care (2008) 1.22
Animal models of sepsis. Virulence (2013) 1.22
Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? Crit Care (2003) 1.18
Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia. Blood (2007) 1.18
Scientific and clinical challenges in sepsis. Curr Pharm Des (2009) 1.14
A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am J Pathol (2004) 1.11
Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J (2006) 1.10
Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res (2010) 1.09
The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci U S A (1994) 1.08
Tissue factor, blood coagulation, and beyond: an overview. Int J Inflam (2011) 1.05
Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA. Am J Pathol (1995) 1.02
C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J Biol Chem (2010) 1.02
Inflammation and haemostasis. Biochem Med (Zagreb) (2012) 1.01
Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol (2008) 1.00
Airway tissue factor-dependent coagulation activity in response to sulfur mustard analog 2-chloroethyl ethyl sulfide. Am J Physiol Lung Cell Mol Physiol (2011) 0.97
Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr Pharm Biotechnol (2011) 0.96
Biology and pathogenesis of thrombosis and procoagulant activity in invasive infections caused by group A streptococci and Clostridium perfringens. Clin Microbiol Rev (2003) 0.95
The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest (1995) 0.93
Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy (2007) 0.92
Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition. Crit Care (2008) 0.92
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr J Hematol Infect Dis (2010) 0.91
Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest (1995) 0.91
Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants. Blood (2005) 0.91
Tissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur mustard analog inhalation. Toxicol Appl Pharmacol (2013) 0.90
The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia. Am J Pathol (2004) 0.89
Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci U S A (1998) 0.88
Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochem J (1996) 0.88
The roles of thrombin and protease-activated receptors in inflammation. Semin Immunopathol (2011) 0.87
Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunopathol (2011) 0.87
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol (2005) 0.86
M type 1 and 3 group A streptococci stimulate tissue factor-mediated procoagulant activity in human monocytes and endothelial cells. Infect Immun (2003) 0.86
Enhancement of fibrinogen-triggered pro-coagulant activation of monocytes in vitro by matrix metalloproteinase-9. Thromb J (2010) 0.84
Mycobacterium tuberculosis infection and tissue factor expression in macrophages. PLoS One (2012) 0.84
The coagulopathy of acute sepsis. Curr Opin Anaesthesiol (2015) 0.82
M protein from Streptococcus pyogenes induces tissue factor expression and pro-coagulant activity in human monocytes. Microbiology (2007) 0.81
Helminths and their implication in sepsis - a new branch of their immunomodulatory behaviour? Pathog Dis (2013) 0.81
Crosstalk between the coagulation and complement systems in sepsis. Thromb Res (2014) 0.80
Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol (2003) 0.80
Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits. J Clin Invest (1996) 0.79
Tissue factor pathway inhibitor and bacterial infection. J Thromb Haemost (2011) 0.78
Tissue factor pathway inhibitor is an inhibitor of factor VII-activating protease. J Thromb Haemost (2012) 0.77
Myeloid tissue factor does not modulate lung inflammation or permeability during experimental acute lung injury. Sci Rep (2016) 0.77
Emerging therapies in severe sepsis. Thorax (2002) 0.77
Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. Vasc Health Risk Manag (2006) 0.77
The role of tyrosine phosphorylation in lipopolysaccharide- and zymosan-induced procoagulant activity and tissue factor expression in macrophages. Infect Immun (1997) 0.76
Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia. J Thromb Haemost (2016) 0.75
Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia. PLoS One (2015) 0.75
Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia. Thromb Haemost (2015) 0.75
Toll-like receptor 9 signaling regulates tissue factor and tissue factor pathway inhibitor expression in human endothelial cells and coagulation in mice. Crit Care Med (2015) 0.75
Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis. Proc Natl Acad Sci U S A (2017) 0.75
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A (1986) 5.83
Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest (1983) 3.47
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest (1987) 3.29
Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock (1991) 2.49
Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A (1986) 2.43
The endotoxin-induced coagulant activity of human monocytes. Br J Haematol (1975) 2.27
Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature (1989) 2.07
Cellular cooperation in endothelial cell thromboplastin synthesis. Br J Haematol (1983) 2.05
Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost (1983) 1.96
Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A (1990) 1.67
Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem (1989) 1.45
Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood (1991) 1.37
DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood (1991) 1.36
Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock (1991) 1.35
Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock (1988) 1.11
Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A (1991) 1.07
Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J Surg Res (1980) 1.07
Detection of the 'hyperdynamic state' of sepsis in the baboon during lethal E. coli infusion. J Trauma (1983) 1.04
The use of a quantitative assay in endotoxin testing. Prog Clin Biol Res (1987) 0.99
The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost (1991) 0.97
Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood (1992) 0.96
Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost (1992) 0.95
Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock (1993) 0.93
Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis (1989) 0.91
Interleukin-6 is a better marker of lethality than tumor necrosis factor in endotoxin treated mice. FEMS Microbiol Immunol (1992) 0.90
Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells. Thromb Haemost (1992) 0.89
Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood (1990) 0.89
Linkage between blood coagulation and inflammation: stimulation of neutrophil tissue kallikrein by thrombin. Biochem Biophys Res Commun (1991) 0.86
Pathophysiologic and biochemical events in disseminated intravascular coagulation: dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost (1989) 0.80
Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid. J Bacteriol (1978) 75.38
Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA. Proc Natl Acad Sci U S A (1972) 57.06
Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci U S A (1973) 25.61
Recircularization and autonomous replication of a sheared R-factor DNA segment in Escherichia coli transformants. Proc Natl Acad Sci U S A (1973) 13.45
Replication and transcription of eukaryotic DNA in Escherichia coli. Proc Natl Acad Sci U S A (1974) 10.51
Phenotypic expression in E. coli of a DNA sequence coding for mouse dihydrofolate reductase. Nature (1978) 8.76
Decay of mRNA in Escherichia coli: investigation of the fate of specific segments of transcripts. Proc Natl Acad Sci U S A (1983) 6.79
Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature (1979) 6.56
Revised interpretation of the origin of the pSC101 plasmid. J Bacteriol (1977) 5.51
Genome construction between bacterial species in vitro: replication and expression of Staphylococcus plasmid genes in Escherichia coli. Proc Natl Acad Sci U S A (1974) 5.47
Structure and genomic organization of the mouse dihydrofolate reductase gene. Cell (1980) 4.25
Indirect selection of bacterial plasmids lacking identifiable phenotypic properties. J Bacteriol (1975) 3.88
Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation (1995) 3.80
Cloning and analysis of strong promoters is made possible by the downstream placement of a RNA termination signal. Proc Natl Acad Sci U S A (1981) 3.77
Isolation of histone genes from unfractionated sea urchin DNA by subculture cloning in E. coli. Nature (1975) 3.70
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest (1987) 3.29
Studies of mouse mitochondrial DNA in Escherichia coli: structure and function of the eucaryotic-procaryotic chimeric plasmids. Cell (1975) 2.80
Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol (1993) 2.27
Outcome and assessment after the modified Fontan procedure for hypoplastic left heart syndrome. Circulation (1992) 2.15
Additional studies on human C5: development of a modified purification method and characterization of the purified product by polyacrylamide gel electrophoresis. Immunochemistry (1972) 2.10
Characterization of the structural gene and putative 5'-regulatory sequences for human proopiomelanocortin. Nature (1982) 2.04
Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration Systemic Sepsis Cooperative Study Group. Crit Care Med (1990) 2.04
Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. J Exp Med (1967) 1.90
A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. J Biol Chem (2001) 1.88
Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol (1995) 1.85
Incidental vesicoureteral reflux in neonates with antenatally detected hydronephrosis and other renal abnormalities. Radiology (1993) 1.83
Video-assisted thoracoscopic division of a vascular ring in an infant: a new operative technique. J Card Surg (1993) 1.82
Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation (1997) 1.81
The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood (2000) 1.80
Comparison of gastrin and histamine on gastric mucosal blood flow. Proc Soc Exp Biol Med (1969) 1.73
Outcome of cardiopulmonary resuscitation in a pediatric cardiac intensive care unit. Crit Care Med (2000) 1.71
Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med (1999) 1.66
Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation (1992) 1.63
Two-stage response to endotoxin infusion into normal human subjects: Correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med (2001) 1.61
A method for selective cloning of eukaryotic DNA fragments in Escherichia coli by repeated transformation. Mol Gen Genet (1974) 1.61
Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost (1991) 1.59
One-stage repair of interrupted aortic arch, ventricular septal defect, and subaortic obstruction in the neonate: a novel approach. J Thorac Cardiovasc Surg (1996) 1.55
Initiation of protein synthesis in bacteria at a translational start codon of mamalian cDNA: effects of the preceding nucleotide sequence. Proc Natl Acad Sci U S A (1980) 1.51
Genetic expression in bacteriophage lambda. 3. Inhibition of Escherichia coli nucleic acid and protein synthesis during lambda development. J Mol Biol (1970) 1.50
Emergent stent placement for acute Blalock-Taussig shunt obstruction after stage 1 Norwood surgery. Cathet Cardiovasc Diagn (1997) 1.50
Macromolecular enzymatic product of NAD+ in liver mitochondria. Proc Natl Acad Sci U S A (1975) 1.48
Chromatography, physical characteristics, and disulfide bonds of euglobulin plasminogen. Arch Biochem Biophys (1966) 1.47
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene (2006) 1.47
Structural organization of human genomic DNA encoding the pro-opiomelanocortin peptide. Proc Natl Acad Sci U S A (1980) 1.44
Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock (1990) 1.39
The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest (1993) 1.38
DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood (1991) 1.36
Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock (1991) 1.35
Effects of acetylsalicylic acid on the canine response to endotoxin. J Pharmacol Exp Ther (1967) 1.33
Genetic organization and functional analysis of the otn DNA essential for cell-wall polysaccharide synthesis in Vibrio cholerae O139. Mol Microbiol (1996) 1.30
The organization of sea urchin histone genes. Cell (1975) 1.28
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol (1999) 1.27
Characteristics of tumor cell bioactivity in oncogenic osteomalacia. Mol Cell Endocrinol (1996) 1.25
gas7: A gene expressed preferentially in growth-arrested fibroblasts and terminally differentiated Purkinje neurons affects neurite formation. Proc Natl Acad Sci U S A (1998) 1.25
The crystal structure of a novel mammalian lectin, Ym1, suggests a saccharide binding site. J Biol Chem (2001) 1.23
Covalent modification of proteins by metabolites of NAD+. Proc Natl Acad Sci U S A (1976) 1.23
Corneal injury threshold to carbon dioxide laser irradiation. Am J Ophthalmol (1968) 1.20
Constitutive activation of integrin alpha 4 beta 1 defines a unique stage of human thymocyte development. J Exp Med (1994) 1.18
The case for water-borne infectious hepatitis. Am J Public Health Nations Health (1966) 1.17
Cardiorespiratory and metabolic responses to liver E. coli and endotoxin in the monkey. J Appl Physiol (1969) 1.16
Comparison of Indium-111 platelet scintigraphy and two-dimensional echocardiography in the diagnosis of left ventricular thrombi. N Engl J Med (1982) 1.16
Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood (2000) 1.15
Divergent inducible expression of P-selectin and E-selectin in mice and primates. Blood (1999) 1.14
Effects of endotoxin on pulmonary capillary permeability, ultrastructure, and surfactant. Surg Gynecol Obstet (1969) 1.14
Determinants of Legionella pneumophila contamination of water distribution systems: 15-hospital prospective study. Infect Control (1987) 1.14
Mesenteric vascular responses to endotoxin in the monkey and dog. Am J Physiol (1970) 1.12
The pulmonary ultrastructure in septic shock. Exp Mol Pathol (1970) 1.12
Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-gamma. Blood (1996) 1.12
Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochem J (2000) 1.10
Nitrification and denitrification processes related to waste water treatment. Adv Appl Microbiol (1975) 1.10
Effect of indomethacin in endotoxin shock in the dog. Proc Soc Exp Biol Med (1967) 1.09
A model for thrombin protection against endotoxin. Thromb Res (1984) 1.09
Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli. Ann Surg (1981) 1.08
Rapid cardiopulmonary support for children with complex congenital heart disease. Ann Thorac Surg (2000) 1.08
Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J Surg Res (1980) 1.07
Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets. J Clin Invest (1970) 1.05
Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med (1993) 1.05
Purification and characterization of streptokinase with studies of streptokinase activation of plasminogen. Biochemistry (1968) 1.05
Detection of the 'hyperdynamic state' of sepsis in the baboon during lethal E. coli infusion. J Trauma (1983) 1.04
Response of the subhuman primate in gram-negative septicemia induced by live Escherichia coli. Surg Gynecol Obstet (1971) 1.04
Comparison of canine responses to Escherichia coli organisms and endotoxin. Surg Gynecol Obstet (1968) 1.04
Effects of ouabain on splanchnic hemodynamics in the rhesus monkey. Am Heart J (1971) 1.03
Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol (1998) 1.03
Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med (1995) 1.03
Cerebrovascular accidents following the Fontan operation. Pediatr Neurol (1995) 1.03
Prevention of death in endotoxin shock by glucose administration. Surg Gynecol Obstet (1974) 1.01
Responses of the baboon to live Escherichia coli organisms and endotoxin. Surg Gynecol Obstet (1977) 1.01
Effects of endotoxin on myocardial hemodynamics, performance, and metabolism. Am J Physiol (1971) 1.01
Continuous versus intermittent furosemide infusion in critically ill infants after open heart operations. Ann Thorac Surg (1997) 1.01
Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J Trauma (1992) 1.00
Effects of endotoxin on myocardial hemodynamics, performance, and metabolism during beta adrenergic blockade. Proc Soc Exp Biol Med (1971) 1.00
Cardiovascular responses of the primate in endotoxin shock. Am J Physiol (1966) 1.00
Plasma endotoxin concentration in healthy primates and during E. coli-induced shock. Crit Care Med (1988) 0.99
Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock (1994) 0.99
Construction of bacterial plasmids that contain the nucleotide sequence for bovine corticotropin-beta-lipotropin precursor. Proc Natl Acad Sci U S A (1978) 0.99